Hipofisina

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hipofisina

Understanding Hipofisina

Hipofisina is a pharmaceutical preparation containing a synthetic form of oxytocin, a peptide hormone naturally produced in the hypothalamus and released by the posterior pituitary gland. In a medical context, this substance is used to mimic the biological effects of the endogenous hormone on smooth muscle tissues, particularly within the reproductive system.

Mechanism of Action

The primary function of Hipofisina involves the stimulation of specific receptors located on the surface of smooth muscle cells. When these receptors are activated, it triggers a series of intracellular signals that lead to increased calcium levels, resulting in muscle contraction.

In the context of the uterus, the sensitivity to this substance increases significantly during pregnancy, reaching its peak near the end of the third trimester. By binding to uterine receptors, Hipofisina promotes the rhythmic contractions necessary for various reproductive processes.

Clinical Applications

Hipofisina is utilized in clinical settings for its ability to influence uterine activity and milk let-down. Its applications generally include:

  • Uterine Stimulation: It is used to initiate or strengthen uterine contractions during the labor process.
  • Postpartum Management: The substance helps the uterus contract after childbirth, which assists in the natural process of returning the organ to its pre-pregnancy size and managing local physiological responses.
  • Lactation Support: It acts on the mammary glands to stimulate the contraction of myoepithelial cells, facilitating the movement of milk into the collecting ducts.

Biological Characteristics

As a synthetic analog of a natural hormone, Hipofisina is designed to be chemically identical to the oxytocin produced by the human body. Because it is a peptide, it is typically administered through routes that avoid digestive degradation, ensuring that the active compound reaches the bloodstream and target receptors effectively.

What side effects are possible with Hipofisina?

Possible Side Effects and Safety Information

The safety profile of Hipofisina (Oxytocin) is officially categorized based on regulatory documents, focusing primarily on maternal and fetal consequences related to its effect on uterine muscle and systemic fluid balance.

Adverse Reaction Classification

Side effects are grouped by frequency and the body system affected, known as System-Organ Classes (SOCs). Officially listed common adverse reactions include temporary gastrointestinal effects such as nausea and vomiting, as well as headache and certain maternal cardiac arrhythmias.

Classification Examples of Officially Listed Effects
Common Nausea, Vomiting, Headache, Maternal Tachycardia/Bradycardia
Uncommon Hypertension

Serious adverse reactions are also documented, often linked to the drug's core action or its anti-diuretic property. These include life-threatening conditions such as Uterine Rupture, severe Water Intoxication with hyponatraemia, and major hemorrhagic defects like Disseminated Intravascular Coagulation (DIC).

Contextual Safety Patterns

The risk profile is specifically associated with the manner and duration of exposure. The regulatory safety data states that rapid intravenous administration may result in acute maternal Hypotension. Conversely, prolonged high-dose infusions are associated with the risk of Water Intoxication due to the drug’s effects on fluid and electrolyte balance. Furthermore, the risk of DIC is documented as being increased when Oxytocin is used for the pharmacological induction of labour.

Population and Systemic Considerations

Safety notes for specific populations are addressed in official labeling, advising caution for patients with pre-existing cardiovascular conditions and those with renal impairment. The safety structure of the medicine emphasizes acute consequences, requiring consideration of potential systemic fluid imbalance and severe trauma related to the reproductive system.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with oxytocin (Hipofisina) is described in regulatory documents based on two major clinical patterns: excessive uterine stimulation and the antidiuretic effect of the medication.

Documented Overdose Manifestations

Uterine Hyperactivity: Overdosage may lead to uterine overstimulation, manifesting as tetanic contractions and persistently increased uterine resting tone. Severe outcomes documented in official labeling include uterine rupture, fetal asphyxia, and fetal death. This risk is noted to be higher in patients with grand multiparity or a uterus that is overdistended.

Water Intoxication: The drug's antidiuretic effect can lead to water intoxication and profound hyponatremia, especially when high doses are given over a prolonged duration. Symptoms of water intoxication documented in official labeling include headache, lethargy, drowsiness, and convulsions.

Required Emergency Actions

The official regulatory action for suspected overdose is the immediate discontinuation of the oxytocin infusion. Management is officially described as symptomatic and supportive, with specific attention required for fluid and electrolyte balance, as no specific pharmacological antidote is known. Emergency medical care is required when severe uterine overstimulation is suspected or when signs of water intoxication, such as confusion or convulsions, appear.

Therapeutic Uses of Hipofisina

Main Uses and Therapeutic Applications

Hipofisina is a medication containing a synthetic version of the hormone oxytocin. It is primarily used in obstetric care to manage various stages of the birthing process and the immediate postpartum period. The medication acts by stimulating the smooth muscle of the uterus, causing rhythmic contractions similar to those observed during natural labor.

Induction and Augmentation of Labor

One of the primary applications of Hipofisina is the induction of labor for medical reasons. This may be necessary when the pregnancy has progressed past the due date or when maternal or fetal health conditions require the delivery to begin. Additionally, it is used for labor augmentation, which involves strengthening or increasing the frequency of uterine contractions when spontaneous labor is not progressing adequately.

Management of the Third Stage of Labor

Hipofisina is frequently used during the third stage of labor, which is the period between the delivery of the infant and the expulsion of the placenta. The medication helps the uterus contract firmly, assisting in the detachment and delivery of the placenta.

Prevention and Treatment of Postpartum Hemorrhage

A critical benefit of Hipofisina is its role in preventing and treating postpartum hemorrhage (excessive bleeding after childbirth). By promoting sustained uterine contractions (uterine tone), the medication helps compress the blood vessels at the site where the placenta was attached, thereby reducing blood loss.

Secondary Benefits and Uses

Support for Breastfeeding

While its primary role is uterine stimulation, oxytocin also plays a part in the "let-down reflex" during lactation. In specific clinical settings, Hipofisina may be used to assist with milk ejection by stimulating the contraction of the myoepithelial cells surrounding the mammary glands, facilitating the flow of milk for breastfeeding.

Diagnostic Applications

In certain cases, the medication may be used in a controlled environment to perform a contraction stress test. This diagnostic procedure evaluates the fetal heart rate response to induced uterine contractions, helping healthcare providers assess the respiratory reserve of the fetus before labor begins.

Regulatory References

  1. National Library of Medicine (NIH) DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Hipofisina? Official Regulatory Information

Hipofisina (Oxytocin) use is strictly limited to the obstetrical domain and is governed by specific regulatory eligibility rules. The eligible population consists of adult females requiring medically indicated labor management, control of postpartum hemorrhage, or management of inevitable/incomplete abortion. Its use is not established or indicated in the pediatric or geriatric populations.

Absolute Non-Eligibility (Contraindications)

Use is strictly prohibited if a patient has a known hypersensitivity to oxytocin or any excipients. The medicine is also contraindicated by official labeling in patients with conditions that pose a mechanical risk, including significant cephalopelvic disproportion (CPD), unfavorable fetal positions (e.g., transverse lie), obstetrical emergencies where surgery is preferred (e.g., vasa previa), or a pre-existing hypertonic uterus.

Restricted and Conditional Use

Use requires extreme caution and specialized monitoring in certain populations. This includes patients with a history of grand multiparity (five or more previous deliveries) or prior uterine surgery (including Cesarean section), due to an increased risk of uterine rupture. Caution is also advised in cases of severe renal impairment due to the potential for water retention, and in those with pre-existing cardiovascular impairment. During lactation, the drug is known to be excreted in small amounts, and use should be carefully considered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Hipofisina (Oxytocin) is primarily characterized by pharmacodynamic interactions, meaning the effects of the drug are modified by other substances. Regulatory documents indicate that Oxytocin does not have documented metabolic or transporter-mediated interactions that significantly alter its plasma exposure.


Official Interaction Statements and Restrictions

Co-administration with Prostaglandins and their analogues is not recommended due to the officially documented risk of an additive effect on uterine smooth muscle. A strict timing rule applies: Oxytocin must not be administered within six hours following the administration of vaginal prostaglandins.

Furthermore, Oxytocin interacts with certain agents that affect the cardiovascular system. Sympathomimetic Vasoconstrictor Agents may have their pressor effect potentiated, which has been associated with reports of severe, sustained hypertension, particularly in the context of caudal block anesthesia. The use of certain Inhalation Anaesthetics, such as Cyclopropane, may also modify the drug's cardiovascular effects, potentially causing maternal sinus bradycardia. Caution is also advised with Drugs prolonging the QTc interval due to the potentially arrhythmogenic properties of Oxytocin.

The official regulatory documents define this interaction structure through specific use-with-caution classifications and mandatory separation requirements, rather than through complex metabolic pathways.

Mechanism of Action

Hipofisina acts as an agonist at the oxytocin receptor (OTR), which is a G-protein-coupled receptor (GPCR) predominantly expressed in the uterine myometrium and mammary gland myoepithelial cells. Upon binding, the activated OTR couples to the Gq/11 alpha-subunit.

This coupling initiates the activation of phospholipase C (PLC), an enzyme that hydrolyzes phosphatidylinositol 4,5-bisphosphate ( PIP2) into the second messengers inositol 1,4,5-trisphosphate ( IP3) and diacylglycerol (DAG). IP3 diffuses to the sarcoplasmic reticulum, binding to its receptor and triggering the release of stored intracellular calcium ( Ca^2+).

The resulting surge in cytoplasmic Ca^2+ binds to calmodulin, forming the Ca^2+-calmodulin complex. This complex activates myosin light chain kinase (MLCK), which phosphorylates the regulatory myosin light chain (MLC). The phosphorylation of MLC facilitates the interaction between actin and myosin filaments. This entire intracellular cascade culminates in the mechanical system-level physiological consequence of smooth muscle contraction, specifically in the uterus (myometrium) and the mammary ducts (myoepithelial cells).

Dosage and Administration Information

Administration Overview

Hipofisina is a medication that is typically administered under the supervision of healthcare professionals. It is provided in a form intended for injection, either through intravenous infusion or intramuscular injection, depending on the specific clinical requirements of the patient.

Clinical Environment

Because the administration of this medication requires precise monitoring, it is generally used within a hospital or clinical setting. Healthcare providers manage the preparation and delivery of the substance to ensure it is used according to standard medical protocols. The process involves continuous observation of the patient's physiological responses during and after the administration.

Preparation and Handling

The medication is contained in ampoules or vials. Before use, the solution is inspected for clarity and the absence of particulate matter. If the medication is to be administered via intravenous infusion, it is diluted in a compatible carrier solution, such as physiological saline or a glucose solution, as determined by the attending medical staff.

Monitoring during Use

During the course of administration, medical professionals monitor specific health parameters. This observation is necessary to track the progress of the treatment and to ensure that the individual's response remains within expected clinical ranges. The duration and frequency of administration are determined by the healthcare provider based on the individual's unique clinical presentation and the desired therapeutic objectives.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hipofisina

This section describes the types of clinical research that have been conducted on Hipofisina (Oxytocin) and the outcomes that were measured, without making any claims about the drug’s performance or effectiveness. The findings presented reflect patterns observed in the studies and do not provide individual predictions.


Evidence for use in Labor Induction and Augmentation

Research has explored the use of Hipofisina in pregnant adults to manage labor that is being initiated or progressing too slowly. Studies, primarily Randomized Controlled Trials (RCTs) and Systematic Reviews, examined outcomes such as the final rate of cesarean section and the time elapsed from intervention to delivery. Findings described patterns where the measurement for time-to-delivery was often lower in groups where the drug was used. However, findings varied regarding the rate of cesarean section between different dosing regimens. A universal, evidence-based standard for optimal dosing remains uncertain, and long-term outcomes are not fully established.


Evidence for use in Postpartum Hemorrhage Prevention

The use of Hipofisina to prevent excessive bleeding after delivery (Postpartum Hemorrhage, PPH) has been the subject of extensive research, including Individual Participant Data (IPD) Meta-analyses of RCTs. These studies examined outcomes such as quantified blood loss volume (PPH ge 500 mL) and the need for additional uterotonic drugs. The data show patterns related to a lower measured incidence of PPH when the drug was observed in comparison to no treatment across large groups. Data are still emerging regarding the optimal prophylactic dose because findings were mixed when comparing different dose levels, and data for certain groups remain insufficient.


Evidence for use in Management of Pregnancy Loss

Hipofisina was studied for its use as an adjunctive therapy in adults experiencing incomplete or inevitable abortion. The evidence, derived from Clinical Trials and Observational Studies, primarily monitored the success rate of complete uterine evacuation and blood loss volume. Studies describe patterns where the drug was used as part of a combination regimen. However, the isolated effect of the drug is limited because research often monitored it within a combination treatment protocol, and comparative evidence is lacking against all newer, non-surgical alternatives.


Research Gaps and Uncertainties

Research for all indications is concentrated on the immediate clinical impact. Consequently, the reported follow-up durations were limited. There is limited information for long-term outcomes for both mother and child following the acute use. Additionally, data for certain groups remain insufficient, particularly for women with complex, coexisting conditions characterized by fluctuating or episodic manifestations, meaning that certainty remains low for conclusions in these specific areas.

Key Studies & References DailyMed: OXYTOCIN injection, solution (Official Drug Labeling)

Frequently Asked Questions (FAQ)

Common questions about Hipofisina (FAQ)

Q: How long can a person safely take Hipofisina?

Hipofisina is used for acute, or short-term, procedures such as inducing labor or managing bleeding after childbirth. The duration of the treatment is managed by a healthcare professional based on the clinical response. It is not intended for long-term daily use.

Q: What kind of monitoring or tests are needed while taking Hipofisina?

When Hipofisina is used to manage labor, the official product information states that certain conditions must be continuously monitored. This monitoring includes checking the fetal heart rate, the resting uterine tone, and the frequency and strength of contractions. This careful supervision is utilized to manage the dosage appropriately during administration.

Q: Are there different strengths of Hipofisina?

The medicine is supplied as a solution containing a specific concentration of 10 USP Oxytocin Units per milliliter. Depending on the clinical purpose—such as inducing labor or controlling postpartum bleeding—the medicine is diluted and administered at various rates and total unit amounts. The precise dosing and administration rate are managed by a healthcare professional.

Q: What are Hipofisina's common side effects?

According to the prescribing information, the most serious potential side effects relate to the uterus, including uterine hypertonicity (excessive muscle tone), spasm, and rupture. Potential side effects for the fetus include changes in heart rate (bradycardia) and rhythm, and potential effects on the central nervous system.

Q: How quickly does Hipofisina start to work?

The medicine works by stimulating the smooth muscle of the uterus to initiate or augment contractions. The time it takes to see the full effect depends on the patient's existing uterine excitability. For controlled procedures, a healthcare professional starts a slow, continuous infusion and gradually adjusts the rate until the desired pattern of contractions is achieved.

Q: Does Hipofisina cause weight gain?

Official documents indicate that rapid weight gain can be a sign of a serious, though rare, condition called water intoxication, which is associated with this medication. If this or other severe symptoms are observed, it is important to notify a healthcare professional promptly.

Q: Is there a generic version of Hipofisina available?

The active pharmaceutical ingredient in Hipofisina is known generically as Oxytocin (a synthetic peptide hormone). The FDA Prescribing Information for this medicine uses the generic name, indicating that the core compound is widely known and used.

Q: Is it normal to feel tired after starting Hipofisina?

The prescribing information lists drowsiness as a potential sign of water intoxication, which is a serious, although uncommon, complication that can occur with use. If this or other severe symptoms are observed, it is important to notify a healthcare professional promptly.

Q: Can Hipofisina affect my sleep?

Regulatory documents mention drowsiness as a potential indication of the serious adverse event known as water intoxication. The medication is generally administered in a clinical setting under constant supervision for a short period of time.

Q: Does Hipofisina have a 'black box warning' from the FDA or similar agency?

According to the FDA Prescribing Information for Oxytocin Injection, the medicine does not have a Boxed Warning (often referred to as a 'black box warning'). This type of warning is reserved for drugs with the most serious risks.

Q: What are the most serious possible side effects of Hipofisina?

The most serious maternal risks described in the official documents include excessive uterine muscle tone (hypertonicity), spasm, and rupture of the uterus. For the fetus, the most serious risks include abnormal slowing of the heart rate (bradycardia) and potential permanent damage to the central nervous system.

Q: Is it true that Hipofisina has a lot of drug interactions?

The official prescribing information explicitly describes potential drug interactions, with a specific focus on the concurrent use of Ergot-Type Oxytocic Drugs. These are medicines used to stimulate uterine contractions and are managed closely when used with Hipofisina.

Q: What if Hipofisina doesn't seem to be working?

The administration of this medicine is closely controlled by a doctor who adjusts the dosage based on the patient's uterine response. If the desired contraction pattern is not established, the rate of infusion may be adjusted or the treatment modified based on the clinical assessment.

Q: Is Hipofisina used for children?

The medicine is indicated solely for use in obstetrical procedures, such as labor, postpartum bleeding, and abortion management. Official regulatory documents do not list any indications or uses for this medication in pediatric patients.

Q: How do I know if I am eligible to take Hipofisina?

Eligibility is determined by a healthcare professional based on the specific condition it is indicated to treat (such as inducing labor) and by reviewing the official list of contraindications with them. Contraindications include conditions such as significant cephalopelvic disproportion or unfavorable fetal positions.

Q: What is the risk of dependence or addiction with Hipofisina?

According to regulatory documents, the medication's active ingredient, Oxytocin, is not classified as a controlled substance. Therefore, the risk of dependence or addiction is considered low based on its classification.

Q: Are there any ingredients in Hipofisina that cause allergic reactions?

The inactive ingredients are listed in the official description section and include chlorobutanol anhydrous (a chloral derivative) and acetic acid. Patients with known sensitivities to these or other ingredients may discuss this with a healthcare professional.

Q: Do studies show Hipofisina is effective?

The medicine is officially indicated for use in the induction of labor, control of postpartum bleeding, and management of abortion. The process of regulatory approval indicates that government bodies have reviewed evidence supporting its use for these specific purposes.

Q: Is Hipofisina a controlled substance?

Regulatory documentation confirms that Hipofisina is not listed or classified as a controlled substance by the FDA or equivalent agencies.

Q: Is Hipofisina an anti-inflammatory drug?

Hipofisina is classified as an oxytocic drug because its primary action is to stimulate the smooth muscle of the uterus and cause contractions. It is not listed or classified as an anti-inflammatory drug.

Q: Why is Hipofisina only available by prescription?

The administration of Hipofisina is described as being strictly controlled, particularly for labor induction, which requires continuous medical supervision in a hospital setting. For this reason, it is only available for use under the direction of a licensed healthcare professional.

Q: Does Hipofisina have a sedative effect?

Regulatory documents list drowsiness as a possible symptom associated with a serious condition called water intoxication. This is not a typical, expected sedative effect and is an adverse event that should be promptly addressed by medical staff.

Q: How does Hipofisina relate to the 'How it works' description?

The medicine functions by interacting with the smooth muscle of the uterus to stimulate contractions. This action is most effective toward the end of pregnancy, during labor, and immediately following delivery.

Q: Are there any official documents that detail the safety classification of Hipofisina?

Yes, the official safety classification, warnings, and contraindications are comprehensively detailed in the FDA Prescribing Information (or equivalent government document) that accompanies the medicine.

Q: Is Hipofisina a biologic medicine?

Hipofisina is a peptide hormone that is prepared by a synthetic process. It is a manufactured version of a naturally occurring hormone.

Q: What are the main contraindications listed for Hipofisina?

The prescribing information lists several situations where the medicine should not be used, known as contraindications. These include cases of significant cephalopelvic disproportion or unfavorable fetal positions where a spontaneous birth is not advised.

Q: Can I take Hipofisina if I have high blood pressure?

The presence of high blood pressure (hypertension) is noted in the official warnings as a medical problem that may make the use of this medicine more complex. Any existing health issues may be discussed with the prescribing physician.

Q: Is it necessary to take Hipofisina with food?

Hipofisina is administered only by intravenous infusion (into a vein) or intramuscular injection (into a muscle). Since it is not taken orally, there are no instructions regarding taking it with food.

Q: Are there populations for whom Hipofisina is specifically not recommended?

Yes, the official prescribing information lists specific maternal and fetal conditions that preclude its use, known as contraindications. These conditions define the populations for whom the medicine is specifically not recommended.

How should Hipofisina be stored and disposed of?

How to Store and Dispose of Hipofisina

Storage and disposal requirements for Hipofisina (Oxytocin Injection) are strictly defined by regulatory labeling to maintain the product's stability and ensure safety.


Official Storage Conditions

  • Temperature: The medicine must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Excursions are permitted between 15 C and 30 C.
  • Handling: It is strictly required to protect the product from freezing.
  • Protection: Hipofisina must be kept in the original carton until the time of use to ensure adequate protection from light.
  • Safety: The product must be kept out of the reach of children at all times.

Disposal of Unused Product

Any unused Hipofisina and related waste materials must be disposed of according to local requirements and institutional procedures. Regulatory documents mandate that disposal follows established pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hipofisina found in:

A-Z Index: